Andrew Dudum on Hims & Hers, Preventive Care and Building a Public Company

Hims & Hers founder and CEO Andrew Dudum joins Harry Stebbings to discuss operating a public company, healthcare products, marketing and international expansion. Dudum speaks as the leader of a company selling healthcare services and products; his medical, product and commercial claims are not independently verified in the interview.

Dudum says he enjoys running a public company because quarterly expectations give his team a demanding benchmark. He sees the need to explain a long-term vision and show progress each quarter as useful discipline. Stebbings notes the criticism public executives can face; Dudum’s preference is a personal view, not a claim that public markets suit every founder.

He recalls that Hims went public relatively early and says he would encourage founders to consider listing if they can predict their business consistently and are prepared for a long-term public-company journey. He does not frame an IPO as a quick exit. The timing of other companies’ listings is his broad comparison, not a verified chronology.

Asked how to reconcile long-term strategy with quarterly pressure, Dudum stresses hiring people who have built through difficult periods. He cites executives who worked through disruption at previous employers and says he looks for resilience and calm under pressure. These are his selection criteria and interpretations of colleagues’ experiences.

Dudum says a scaling founder can be tempted to hire senior strategists with impressive credentials while losing hands-on operating capacity. He recalls making hiring mistakes and prefers people who care about the mission and can execute. His view does not imply that experience at a larger company is inherently unhelpful.

On ‘founder mode,’ he rejects personally reviewing every decision. He argues that leaders should hire people who are stronger than they are in their specialties, then deliberately go deep on a small number of critical decisions. A growing leader’s role changes, he says, so developing successors for previous responsibilities is important.

Stebbings asks how many people Hims might employ in 2030. Dudum estimates roughly 2,000–3,000, compared with about 2,000 at the time of the interview. He distinguishes software functions from physical pharmacy fulfillment and licensed clinical oversight. The staffing figure is a forecast, not a commitment or verified assessment of future jobs.

Dudum says the company uses AI in engineering, customer support and design. He estimates that a design team can produce three to four times as much marketing material using AI-assisted workflows. This is his company’s experience and estimate; the interview does not supply an independent productivity study or quality comparison.

He also describes AI support for clinical workflows, including guidance and standardization around decisions made by doctors. Dudum claims this could improve efficiency and quality, but supplies no clinical evaluation, error rates or evidence of outcomes. His claims about patient volume and relative scale are also unverified; the discussion does not establish that AI is safe or appropriate for a particular patient.

Stebbings asks whether weight loss accounts for most of Hims & Hers. Dudum says it is not a majority and describes a portfolio spanning several clinical categories. He predicts continued diversification, but does not provide a category-level revenue breakdown in the interview; the claims about growth and durability are his company assessment.

Dudum compares the company’s categories with a venture portfolio: some experiments receive more funding, others are reduced, and some are protected for longer exploration. He says health products, diagnostics and consumer preferences change, so management must revisit the mix. This is his operating framework, not evidence that every experiment is clinically effective.

Asked what he would change, Dudum says the company does not need to be first in every category; he prefers entering when it has confidence in protocols, supply and quality. He mentions possible future peptide offerings. Those plans and his assurances about safety are company claims, not evidence of regulatory authorization, clinical effectiveness or suitability for use.

Stebbings challenges Dudum on the price of GLP-1 medicines. Dudum describes a lower price for a specific Wegovy pill through a partnership and says he wants both quality and affordability. The exchange refers to different products, periods and payment arrangements; it does not establish an equivalent price reduction for every formulation or patient.

Dudum describes a partnership involving Grail’s Galleri blood test and says he and family members have used it. He makes claims about cancer detection and possible lower prices. The interview supplies no sensitivity, specificity, false-positive, outcome or eligibility data, so his account does not establish that the test reliably detects all cancers or that annual screening benefits everyone.

He attributes part of a reported reduction in GLP-1 prices to pressure from consumers, his company, government and drugmakers. That causal account and his headline percentage are his interpretation; products, list prices, cash prices, coverage and time periods can differ. The conversation does not independently isolate Hims & Hers’ effect on prices.

Discussing preventive care, Dudum says he is interested in tests and treatments for underserved needs and describes a partnership with Prenuvo. He suggests that future therapies might reduce cardiovascular risk. His claims about statins, investigational injections and their effects are not clinical evidence, and the interview does not establish that any treatment eliminates risk or is suitable for all people.

Dudum recounts his father’s cancer experience and says he personally uses whole-body imaging. He acknowledges that some clinicians believe broad screening is not yet ready for mainstream use and that such tests are imperfect. His personal decision and commercial partnership do not establish clinical benefit, appropriate frequency or the balance of false positives and follow-up harms.

Stebbings asks whether a general AI assistant could become a threat to Hims. Dudum argues that licensed clinicians, pharmacy fulfillment and physical infrastructure may remain important, while conversational tools could direct users to specialists and services. His picture of future partnerships is a business hypothesis, not an established agreement or evidence that an AI system can diagnose patients safely.

Dudum says his company has not seen dramatic changes in acquisition from newer AI interfaces and describes television, sports and word of mouth as channels for reaching first-time patients. He expects chat-based advertising to develop over time. These are company observations and predictions; the interview does not provide channel-level results or independently verify patient claims.

Asked about unconstrained marketing, Dudum jokes about sponsoring Ferrari and says a global sponsorship may become more useful as the company expands internationally. Stebbings raises an Eucalyptus acquisition around $1.5 billion, which Dudum describes as approximately right. The interview does not establish the final consideration, financing or integration results.

Dudum says he had known Eucalyptus’s founder Tim for several years and praises his willingness to test markets and pull back when experiments failed. He describes the target’s position across several countries and says Hims’ balance sheet helped fund expansion. Those market-leadership, cash-flow and transaction claims are his account, not independently verified performance data.

On acquisition risk, Dudum acknowledges a fine line between moving aggressively and losing control. He says discomfort prompts continuous evaluation and adjustment, and draws an analogy to rowing. His belief that pushing near that line is productive is a management philosophy, not a guarantee that a transaction will integrate successfully.

Dudum recalls launching commodity skincare and supplements in the early years and later deciding that broad assortment alone was not enough. He says the company now looks for differentiation, including personalization or difficult-to-provide products. These are his retrospective business judgments, not independent proof of product quality or patient benefit.

Asked what he learned about brand marketing, Dudum argues that a one-off campaign can be enjoyable yet difficult to connect to durable results. He prefers consistent exposure in varied places over time. His description is an experience-based marketing thesis; he does not provide a controlled measurement of campaign effectiveness.

He says communications teams can become bored repeating a message before customers or new employees have absorbed it. In his view, a recognizable brand repeatedly explains its purpose, customer and value in different ways. Stebbings agrees that new team members need to hear the message with the same conviction.

Dudum says the company hopes to form stronger views about preventive care using information from the patients it serves. He cites large daily patient volumes and imagines personalized guidance. These figures and the claimed insights are his account; the interview provides no independent evidence that its data supports particular recommendations or improves health outcomes.

Stebbings proposes free preventive assessments as a way to reach people and build relationships. Dudum says that resembles his vision and describes the acquisition of YourBio Health and plans for home blood collection and laboratory processing. The device’s performance, clinical validity, costs and future availability are company claims, not independently assessed in the discussion.

Dudum imagines offering a broad panel at low or no cost and using information, including genetic or cancer-risk measures, to guide next steps with a clinician. The proposed panel, prices and processing capacity are future plans. The interview does not establish that any particular test is indicated for an individual or that genetic scores reliably predict an individual outcome.

Dudum recounts a friend’s lipoprotein(a) result and family history to illustrate why he values access to information. He makes specific claims about thresholds and a future heart attack, but the anecdote lacks units, clinical context and independent evidence. It cannot determine an individual’s risk or treatment; interpretation depends on a qualified clinician and the person’s circumstances.

Asked about incentives in US healthcare, Dudum criticizes the existing system and argues that direct customer payments align Hims & Hers with patients. Stebbings challenges whether a seller of treatments can have conflicting incentives. Dudum says he wants a durable relationship that may include saying a treatment is not appropriate; the interview does not independently evaluate the company’s incentives or outcomes.

Dudum says lab testing is currently offered near cost and expects it to remain a low-margin entry point as the company builds infrastructure. That is his account of the economics and a future intention; no audited product-level margin is supplied. He sees access to information as a way to support a longer patient relationship.

Stebbings asks why Hims & Hers attracts criticism. Dudum says he believes pressure on pharmaceutical distribution and pricing creates friction and credits the company with contributing to change. He declines to assess a competitor’s strategy. His explanation of public criticism and role in price changes is a self-interested interpretation, not an independently established causal finding.

Dudum predicts more healthcare distribution will move toward direct consumer channels with transparent pricing and access to clinicians. He criticizes the complexity of insurance and pharmacy-benefit arrangements. This is his vision and critique; the interview does not establish that direct-pay services are appropriate, cheaper or more accessible for every patient.

Asked about Epic and health records, he says many customers begin their care journey without extensive legacy records and argues that building an early relationship matters. His statements about customer history and the relevance of existing systems are his company perspective, not a representative study of patients or record interoperability.

The conversation turns to food. Dudum and Stebbings express concerns about processed food, costs and access to healthier options; Dudum also praises the current US administration’s approach. His broad claims about ingredients, specific health effects and policy success are opinions and are not independently assessed in the interview.

Dudum describes the cost of buying food for his children as an example of the difficulty some families face. He favors local food and easier access to nutritious options. This is a personal observation, not evidence that a particular diet, product or policy is suitable for everyone.

In the quick-fire round, Dudum says he would have pushed the organization to change its processes with AI earlier, particularly in customer care and provider quality. He regards falling retention as more concerning than rising acquisition costs, although he believes scale and new channels can sometimes improve acquisition efficiency. These are his management judgments, not measured outcomes.

Asked what he would tell his younger self, Dudum says to trust his instincts while accepting that a long journey brings ups and downs. He emphasizes persistence. His advice is a retrospective reflection rather than a formula for entrepreneurial success.

On fatherhood, Dudum recalls a story about young children valuing time spent playing with parents. He says he tries to be present and join his children in what they are doing. He offers this as personal advice, not a universal parenting rule.

Stebbings thanks Dudum and closes the conversation. The interview presents the company’s ambitions and the founder’s views; its healthcare claims, prices and financial figures would require independent clinical, regulatory or financial verification.